Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 13Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Advanced Solid Tumors 4Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Childhood Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

pembrolizumab 6Nivolumab 3budigalimab 2Paclitaxel 2Ipilimumab 2Docetaxel 2venetoclax 1tislelizumab 1talazoparib 1spartalizumab 1rovalpituzumab tesirine 1regorafenib 1obinutuzumab 1naptumomab estafenatox 1fludarabine 1epacadostat 1durvalumab 1cabozantinib 1Platinum 1Levoleucovorin 1Leucovorin 1Interleukin-2 1IPI-549 1Gemcitabine 1Fluorodeoxyglucose F18 1Everolimus 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × talazoparib × Other solid neoplasm × Clear all
NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡